Hallmarks of cancer, which include dysregulation of cell cycle, apoptosis and epigenetic remodeling are of tumor and of microenvironment origins. Although these hallmarks favor cancer survival and growth, they also confer specific addictions or vulnerabilities to cancer cells that can be exploited for therapies with regard to cancer heterogeneity and specificity.
We work on identifying vulnerabilities that are consequent to the adaptation of cancer cells to survival and resistance within their ecosystem. More precisely, we focus on major molecular mechanisms involved in resistance/escape of cancer cells to death, such as p53 pathway, BCL2 family and epigenetic modifiers networks. We develop original culture models (ex vivo coculture models, PDX) and cutting-edge technologies (Multispectral IHC, multiparameter flow cytometry, scRNASeq). Our research models are mature B-cell malignancies such as Multiple Myeloma and Mantle Cell Lymphoma.
Company Details
- Employees
- 8
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Team 11 : Remove-B (Crci2na) Questions
Team 11 : Remove-B (Crci2Na)'s website is https://crci2na.univ-nantes.fr/en/research/team-11
Team 11 : Remove-B (Crci2Na)'s LinkedIn profile is https://www.linkedin.com/company/team-11-remove-b-crci2na
Team 11 : Remove-B (Crci2Na) has
8 employees.
View email and phone details for 8
employees at Team 11 : Remove-B (Crci2Na).
Team 11 : Remove-B (Crci2Na)'s industry is
Research Services
Team 11 : Remove-B (Crci2Na)'s top competitors are
Inserm Grand Ouest,
Résidence La Chézalière - Maison De Retraite Médicalisée,
Siric Iliad,
Institut De Cancérologie De L'ouest (Ico),
Crci2na,
Sinensis Innovations Corp,
Go-Ev,
Momola Food,
Biosit / R&d Bio Santé,
Dextreg.
Team 11 : Remove-B (Crci2Na)'s categories are Research Services
